MetaVia Inc. Common Stock

MTVANASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
2.57 USD
↗ 0.12 (4.90%)AT CLOSE (11:59 AM EDT)
2.51
↘ 0.06 (2.18%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
2.51
↘ 0.06 (2.18%)
🔴Market: CLOSED
Open?$2.65
High?$2.79
Low?$2.32
Prev. Close?$2.45
Volume?16.0M
Avg. Volume?7.5M
VWAP?$2.92
Rel. Volume?2.13x
Bid / Ask
Bid?$2.42 × 300
Ask?$2.51 × 700
Spread?$0.09
Midpoint?$2.47
Valuation & Ratios
Market Cap?13.3M
Shares Out?5.2M
Float?3.4M
Float %?65.2%
P/E Ratio?N/A
P/B Ratio?1.46
EPS?-$2.54
Dividend?0.00%
Ex-Dividend?N/A

MetaVia Inc. Common Stock (MTVA) trades at $2.57 per share. The technical outlook is "Neutral" and the fundamental picture shows "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest MTVA is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Themes
Biotech - Drug Development›Metabolic & Cardiometabolic
Employees
8
Market Cap
13.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.metaviatx.com
Listed
2016-08-04
Address
545 CONCORD AVENUE
CAMBRIDGE, MA 02138
Phone: (857) 702-9600
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
75
Piotroski F-Score?0/9Weak
Altman Z-Score?-15.78Distress
Confidence?38%Very Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?2.06%Low
Short Interest?69.2K
Days to Cover?1.0
Free Float3.4M
Avg Daily Volume135.4K
Settlement Date2026-05-15
Financial Health
Current Ratio?2.73Strong
Quick Ratio?2.73Strong
Cash Ratio?2.64Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
88
1.46CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-144.7%WEAK▾
ROA?
S&P
3
-91.2%WEAK▾
Cash Flow & Enterprise
FCF?$-15146000
Enterprise Value?$-439569
Fundamentals ratios updated end of day
MarketsMoversWatchlist